Volume 53, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Skin test reactivity to two commercial preparations of leishmanin was evaluated in leishmaniasis patents from Ethiopia () and Nicaragua (probably complex). The purpose of using different preparations of was to evaluate whether skin test antigens could generally be used to detect leishmaniasis due to and . One preparation was superior in identifying the majority (83–90%) of confirmed cases of local cutaneous leishmaniasis (LCL) from Ethiopia. In vitro responses to promastigotes of spp. correlated well with leishmanin positivity to this preparation. The skin test antigen, which performed less well (showing a positive result in only 50% of the LCL patents), showed promise when used to test active and cured cases of leishmaniasis in Nicaragua (positive result in 92% of the active and cured patents). Cross-reacting spp. may be considered for use in the preparation of standardized leishmanin antigen; however, differences in the commercial preparation or the diluent in which the parasites are prepared may affect antigenicity and thus its efficacy in detecting different forms of leishmaniasis in different geographic areas.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error